FTSE 100 Rises to 10,729.78 as AstraZeneca and BT Offset NatWest's Slump
FTSE 100 closed at 10,729.78, up 0.07%, with AstraZeneca (AZN) rising 7% on strong Q3 results and BT (BT) up 6.7%. NatWest (NWG) fell 9% due to missed earnings expectations. The index outperformed global markets amid a tech selloff.
How this was made
The 30-second read
Why it matters
The earnings releases provide fresh price catalysts for the highlighted stocks, creating short‑term trading opportunities.
Market read
Defensive UK stocks outperformed, offsetting a global tech sell‑off and supporting the FTSE 100's first monthly gain in three months.
What to watch
Potential impact of upcoming BoE rate decision and UK budget on banking and consumer stocks.
Background
FTSE 100 posted a modest gain on Friday, driven by strong earnings from AstraZeneca and BP, while NatWest dragged the index down.
Ticker impact
AstraZeneca reported Q3 revenue of $16.2B, EPS $2.79 and reaffirmed full-year guidance, sending its shares up ~7% on the day.
likely further upside as investors price in the guidance reaffirmation and cost‑saving program.
Earnings beat and guidance reaffirmation are fresh primary disclosures for a large‑cap pharma, driving a material price move.
NatWest Group posted Q3 net interest income miss and higher loan impairments, causing its shares to fall nearly 9% on the day.
likely continued pressure as margin concerns persist and the stock may test lower support levels.
The earnings miss is a fresh primary disclosure for a major UK bank, resulting in a large intraday decline.
BP reported record Q3 profit of $8.46B, beating expectations and lifting its shares about 0.5%.
likely modest further gains if oil prices stay firm.
Earnings beat is a fresh disclosure, but the price move is modest.
Market effects
Pharma and energy sectors gain, while banking and mining lag, reinforcing FTSE's defensive tilt.
UK equities rise modestly as defensive heavyweights offset tech sell‑off.
FTSE 100 outperforms global peers, highlighting the value of sector‑weighted exposure during AI‑related tech weakness.
Counterpoint
Investors may view the pharma rally as over‑optimistic given broader market volatility.
Key entities
- companyAstraZeneca
Pharmaceutical giant reporting strong Q3 results.
- companyNatWest Group
UK bank missing interest income expectations.
- companyBT Group
Telecoms firm with a large intraday rally.
- companyBP
Energy major posting record quarterly profit.
